Main Menu

Dr Andrew Feber

Team Leader

The alt text
Dr Andy Feber leads the Translational Epigenetic group at the ICR, he is also Deputy Director of clinical genomics at The Royal Marsden, NHS Foundation Trust. His research focuses on the role changes in the epigenome play in cancer development and how these changes can be used as biomarkers to improve early cancer detection, diagnosis and the monitoring of response to therapy. Team: Translational Epigenetics
+44 20 3437 6020 ORCID 0000-0001-5282-0498

Biography

Dr Andy Feber leads the Translational Epigenetic group at the ICR, he is also Deputy Director of Clinical Genomics at The Royal Marsden, NHS Foundation Trust.

He obtained her PhD under the supervision of Professor Colin Cooper at The Institute of Cancer Research in Sutton, where he studied the genomics of urological cancers.

On completion of his PhD, Dr Feber joined Dr Tony Godfrey at Mount Sinai Medical School, New York, as a Postdoctoral Research Fellow and subsequently Assistant Professor. He continued his postdoctoral training, returning to the UK in 2008 to the laboratory of Professor Stephan Beck, at the UCL Cancer Institute, London, to investigate the role of DNA methylation in cancer development and progression.

In 2011 he set up a Translational Uro-Oncolgy research group at UCL with Professor John Kelly, and from 2017 he was an Associate Professor in the Department of Targeted Intervention, Division of Surgery and Interventional Science, UCL. Where he still holds an Honorary appointment.

His research interests focus on understanding the role the epigenome plays in cancer development, and how changes in the epigenome can be used as non-invasive biomarkers for the detection, diagnosis and monitoring of patients with cancer.